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EXPERT OPINION
Abstract: Alzheimer’s disease (AD) is the most common cause of dementia, accounting for
25 million cases worldwide. Until recently, the pharmacotherapy of AD was limited to the
use of cholinesterase inhibitors (ChEIs) that are approved only for the mild to moderate
stages of the illness. Memantine, an NMDA receptor antagonist has been found to be effective,
both as monotherapy and in combination with donepezil, in the treatment of patients with
moderate to severe stage AD. More recent studies have examined the role of memantine in
the treatment of the mild to moderate stages of the disease, although the collective results of
these studies remain inconclusive. Available pharmacoeconomic data indicate that treatment
with memantine is cost-effective when compared with no treatment in patients with moderate
to severe AD. Memantine treatment is predicted to be associated with lower costs of care,
longer time to dependence and institutionalization, and gains in quality-adjusted life-years.
In this article, we review the evidence for the use of memantine in patients with AD, ranging
from the mild to severe stages of disease.
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Introduction
Alzheimer’s disease (AD) is the most common etiology of dementia, accounting for
approximately 25 million cases worldwide (Wimo et al 2003). About 6.1% of the
world’s population over the age of 65 years is estimated to develop dementia (about
0.5% of the worldwide population). The number of new cases of dementia in 2000
was approximated at 4.6 million. In the United States population alone, there were
about 4.5 million persons with AD (Hebert et al 2003). The cost of the disease to the
individual and to society is immense. In the United States alone, the total cost of
caring for patients with AD was calculated in 2000 to be over US$100 billion annually
(Johnson et al 2000). Age remains the number one risk factor for the development of
AD, as evidenced by the sharp prevalence increase from 6.1% of the population ≥65
years of age to 40% of the population ≥85 years of age (Jorm 1991; Wimo et al
2003). As the world population ages, the number of people suffering from this disease
is predicted to increase significantly. Forecasts indicate that the number of demented
elderly will increase from the present number of 25 million to 63 million by 2030
(41 million in less developed regions) and to 114 million in 2050 (84 million in less
developed regions) (Wimo et al 2003).
Recent reports have emphasized that AD often goes unrecognized and undiagnosed
until later in the illness (Small et al 1997; Hebert et al 2003). Early diagnosis and
treatment can reduce the disability due to the disease and prepare patients and their
families for future challenges with the disease (Grossberg and Desau 2003). Until
recently, the pharmacological options for the treatment of cognitive deficits in AD
were limited to the use of the cholinesterase inhibitors (ChEIs) tacrine, donepezil,
rivastigmine, and galantamine, which were all approved for mild to moderate stage
AD (Cummings 2003). Data concerning the benefits of these drugs in the more
advanced stages of the disease are limited. Moreover, the side-effect profile of the
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ChEIs – including gastrointestinal disturbances like nausea,
vomiting, diarrhea and anorexia – restrict their use. Several
other potential agents, including antioxidants, ginkgo biloba,
non-steroidal anti-inflammatory agents (NSAIDS), lipid-
lowering agents, hormones, chelating agents, growth factors,
and anti-amyloid strategies, have not yet demonstrated
efficacy for AD (Doraiswamy 2002). In this article, we
review the evidence for the use of memantine hydrochloride,
an NMDA receptor antagonist, in the treatment of AD.
Mechanisms of action
and pharmacokinetics
During normal synaptic transmission the NMDA receptor
is activated by the binding of glutamate, the major excitatory
neurotransmitter in the central nervous system (CNS)
(Lipton 2004). Depolarization of the postsynaptic neuron
leads to removal of the magnesium ion blockade from the
NMDA channel, allowing the influx of monovalent and
divalent cations (Lipton 2004). The entry of calcium is
critical for learning and memory formation by induction of
long-term potentiation (LTP) (Danysz and Parsons 2003).
However, excessive influx of calcium ions may result in
excitotoxic cell damage. Excitotoxicity is defined as the
excessive exposure of neurons to glutamate or
overstimulation of its membrane receptors, leading to
neuronal injury or death (Lipton 2004).
Memantine (1-amino–3, 5-dimethyladamanantate) is an
adamantane derivative that blocks the NMDA receptor-
associated ion channel similar to magnesium by binding to
or near the magnesium-binding site (Lipton 2004).
Memantine is an uncompetitive, low-affinity, open-channel
blocker that enters the receptor channel preferentially when
it is excessively open (Lipton 2004).
Equally important is the “off-rate” of memantine, which
is relatively fast, resulting in low accumulation in the channel
and minimal interference with normal synaptic transmission
(Chen et al 1992; Danysz and Parsons 2003; Lipton 2004).
Memantine is classified as an uncompetitive antagonist, as
it needs prior activation of the NMDA receptor by glutamate
before it can access the binding sites on the receptor. It also
has lower affinity for the receptors than some other potent
NMDA receptor channel blockers like phencyclidine (PCP),
ketamine, and MK-801 (Rogawski and Wenk 2003). These
factors may allow memantine to block channel activity
induced by low, tonic levels of glutamate – an action that
might contribute to symptomatic improvement and protect
against weak excitotoxicity – while sparing synaptic
responses required for normal cognitive functioning and
enhancing tolerability (Rogawski and Wenk 2003).
The putative neuroprotective effects of memantine have
been studied in several rodent models. In a rat model of
transient forebrain ischemia, memantine reduced cerebral
infarct size and hippocampal cell loss in a dose-dependent
manner (Seif el Nasr et al 1990). In a rat model of
progressive functional neurodegeneration (bilateral
clamping of the carotid arteries) memantine pre-treatment
prevented neuronal necrosis and protected against NMDA-
specific learning and memory deficiencies in the Morris
water maze (Heim and Sontag 1995). Finally, chronic
administration of memantine prevented the decline in
cortical choline acetyltransferase activity associated with
injection of NMDA into the nucleus basalis magnocellularis
and attenuated reference memory deficits in the radial maze
produced by entorhinal cortex lesions (Wenk et al 1997).
Memantine is well absorbed from the gastrointestinal
tract after oral administration, and its absorption is
unaffected by food (Forest Laboratories 2003). It reaches a
maximum plasma concentration (Cmax) after a single dose
in 3–7 hours, and it has a plasma half-life of about 60–80
hours. The dose–plasma concentration relationship is linear
in the therapeutic dose range of 10–40 mg daily (Forest
Laboratories 2003). It is 45% protein bound and is partly
metabolized by the liver. About 48% of the drug is excreted
unchanged in the urine. The remainder of the drug is
metabolized by the liver into three polar compounds that
possess minimal NMDA receptor antagonist activity, ie, N-
glucuronide conjugate, 6-hydroxy memantine, and 1-
nitroso-deaminated memantine. A total of 74% of the
administered dose is excreted as the sum of the parent drug
and the N-glucuronide conjugate. Memantine is mainly
excreted via the kidneys (74%) after undergoing active
tubular secretion moderated by pH dependant tubular
reabsorption. In elderly volunteers with reduced renal
function, a significant correlation has been observed between
creatinine clearance and total renal clearance of memantine,
indicating that patients with severe renal disease may require
lower dosages (see Dosing Schedule).
Memantine does not induce the cytochrome P450
isozymes CYP1A2, CYP2C9, CYP2E1, and CYP3A4/5
(Forest Laboratories 2003). Studies have shown that
memantine produces minimal inhibition of CYP450
enzymes CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1,
and CYP3A4, indicating that no pharmacokinetic
interactions with drugs metabolized by these enzymes are
expected. The clearance of memantine is reduced by aboutNeuropsychiatric Disease and Treatment 2007:3(2) 247
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80% under alkaline urine conditions at pH 8, and hence
alterations of urine pH towards the alkaline state may lead
to an accumulation of the drug with a possible increase in
adverse effects. Drugs that alkalinize urine like carbonic
anhydrase inhibitors and sodium bicarbonate may reduce
renal elimination of memantine (Forest Laboratories 2003).
The mean cerebrospinal fluid to plasma concentration for
memantine is about 50% (Kornhuber and Quack 1995). No
drug–drug interactions between memantine and ChEIs have
been observed, and hence they can be used together safely
without dose adjustment (Periclou et al 2004).
Memantine for moderate to severe
AD
Memantine has been evaluated in moderate to severe AD
patients in four major studies: 3 involving memantine
monotherapy and 1 involving combination therapy with
donepezil. The first was a trial conducted in 166 patients
admitted to 6 nursing homes and a psychiatric hospital in
Latvia (Winblad and Poritis 1999). The three other trials
were conducted in community dwelling subjects and
involved samples of 252 subjects (Reisberg et al 2003), 350
subjects (van Dyck et al 2007), and 404 subjects (Tariot et
al 2004). The efficacy results of these studies are
summarized in Table 1 and the various rating scales utilized
are detailed in Table 2.
Monotherapy studies
Winblad and Poritis study
This was a 12-week, placebo-controlled trial of memantine
10 mg daily, conducted in nursing home residents and
psychiatric hospital patients. Men and women (N=166)
between the ages of 60 and 80 years were included if they
met DSM-III-R criteria for dementia (APA 1987). Further
inclusion criteria were severity stages 5-7 of the Global
Deterioration Scale (GDS) (Reisberg et al 1982), Mini-
Mental State Examination (MMSE) (Folstein et al 1975)
score of <10 points, duration of dementia >12 months, and
Table 1         Mean change on outcome measures in clinical trials of memantine
Outcome measures
Study Treatment arm Subject CIBIC- CGIC ADAS- SIB ADCS- BGPcare
sample Plus Cog ADL
Moderate to severe AD
Monotherapy studies
Winblad and Poritis 1999 Memantine 82 3.21
c –3.1
a
Placebo 84 3.64 –1.1
Reisberg et al 2003 Memantine 126 4.5a –4.0c –3.1b
Placebo 126 4.8 –10.1 –5.2
van Dyck et al 2007 Memantine 178 4.3 –2.0 –2.0 0.5
Placebo 172 4.6 –2.5 –2.7 1.4
Combination therapy studies
Tariot et al 2004 Memantine 203 4.41
a 0.9
c –2.0
b 0.8
c
Placebo 201 4.66 –2.5 –3.4 2.3
Mild to moderate AD
Monotherapy studies
Peskind et al 2006 Memantine 201 4.2
b –0.8
a –2.9
Placebo 201 4.5 1.1 –3.0
Combination therapy studies
MEM-MD-12 Memantine 214 4.4 0.4 –2.9
Placebo 213 4.4 1.1 –2.9
Notes: All values are from intent to treat, last observation carried forward analyses. Backchine et al (2005) study is omitted from this table, as mean change data are
unavailable.
Differs from placebo group: ap<0.05, 
bp<0.01, 
cp<0.001
Abbreviations: CIBIC-Plus, Clinicians Interview Based Impression of Change with Caregiver Input (higher score indicates greater deterioration); CGIC, Clinical
Global Impression of Change (higher score indicates greater deterioratieon); ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale (positive score
indicates deterioration); SIB, Severe Impairment Battery (positive score indicates improvement); ADCS-ADL, Alzheimer’s Disease Cooperative Study–Activities for
Daily Living Inventory (positive score indicates improvement); BGPcare, Behavioral Rating Scale for Geriatric Patients care dependence subscore (positive score
indicates deterioration).Neuropsychiatric Disease and Treatment 2007:3(2) 248
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the absence of CNS-active drug use within 14 days prior to
the start of the trial. Primary endpoints were the Clinical
Global Impression of Change (CGI-C) (Schneider et al
1997) rated by the study physician, and the Behavioral
Rating Scale for Geriatric Patients (BGP), subscore “care
dependence”, rated by the nursing staff (van der Kam and
Hoeksma 1989). Secondary endpoints included the modified
D-Scale (Arnold/Ferm) (Ferm 1974).
The intent to treat (ITT) sample comprised 166 patients
of which 151 completed the protocol. At 12-week ITT
endpoint analysis, 82 subjects had received memantine, 10
mg daily, and 84 had received placebo. Dementia
classification was 49% of the Alzheimer type and 51% of
the vascular type, based on CT scan and Hachinski ischemia
score (Rosen et al 1980). A positive response (ie,
improvement) in the CGI-C was seen in 73% of memantine-
treated vs 45% of placebo-treated patients (stratified
Wilcoxon p<0.001), independent of the etiology of
dementia. Twenty-one per cent of the patients were rated as
much improved in the memantine group compared with 11%
in the placebo group, again independent of dementia
etiology. As shown in Table 1, the mean CGI-C score was
significantly better for memantine-treated (3.21) than for
placebo-treated (3.64) patients (p<0.001). The results in the
BGP subscore “care dependence” were 3.1 points
improvement under memantine and 1.1 points under placebo
(p=0.016). Responder analyses showed that for the CGI-C,
76% of memantine-treated patients were classified as
responders (ie, showing any improvement) compared with
44.7% in the placebo group. On the BGP “care dependence”
subscore, by contrast, 65.3% of patients were classified as
responders compared with 39.5% in the placebo group.
Coincident response in the two primary outcome measures
was observed in 61.3% (memantine) vs 31.6% (placebo).
Secondary endpoint analysis of the D-Scale assessing basic
activities of daily living (ADL) functions indicated that for
every item, response rates were greater for memantine than
placebo, reaching statistical significance (p<0.05) in 8 of
16 items.
Reisberg et al study
The first pivotal trial of memantine in the United States was
a 28-week, placebo-controlled outpatient trial of memantine
10 mg twice daily. It enrolled subjects with moderate to
severe AD who were aged 50 years or more, living in the
community, and had a diagnosis of probable AD based on
US National Institute of Neurological and Communicative
Disorders and Stroke-Alzheimer’s Disease and Related
Table 2              Common rating scales used in dementia studies
Score range
Scale Reference Assesses Low High Higher score indicates Interviewee
ADCS-ADL Galasko et al 2005 Activities of daily living 0 78 Better ADL performance Caregiver
ADAS-Cog Rosen et al 1980 Cognition 0 70 Worse cognition Patient
BGP van der Kam and Cognition, function, and 0 70 Worse functioning Patient
Hoeksma 1989 behavior
CGI-C Schneider et al 1997 Global change 1 7 Global worsening Patient, Caregiver
a
CIBIC-Plus Schneider et al 1997 Global change 1 7 Global sorsening Patient, Caregiver
FAST Sclan and Reisberg 1992 Global functioning 1 7 Poorer functioning Patient, Caregiver
GDS Reisberg et al 1982 Global functioning 1 7 Poorer functioning Patient, Caregiver
MMSE Folstein et al 1975 Cognition 0 30 Better cognition Patient
NPI Cummings et al 1994 Neuropsychiatric symptoms 0 144 Greater disturbance Caregiver
SIB Schmitt et al 1997 Cognition 0 100 Better cognition Patient
aCaregiver interview is not required for CGI-C
Abbreviations: ADCS-ADL, Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory; ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive
subscale; BGP, Behavioral Rating Scale for Geriatric Patients; CGI-C, Clinicians Global Impression of Change; CIBIC-Plus, Clinician’s Interview Based Impression of
Change, with Caregiver input; FAST, Functional Assessment Staging Scale; GDS, Global Deterioration Scale; MMSE, Mini Mental State Examination; NPI,
Neuropsychiatric Inventory; SIB, Severe Impairment Battery.Neuropsychiatric Disease and Treatment 2007:3(2) 249
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Disorders Association (NINCDS-ADRDA) criteria
(McKhann et al 1984) and Diagnostic and Statistical Manual
of Mental Disorders (DSM) 4th edition (APA 1994). All
subjects also had a MMSE (Folstein et al 1975) score
between 3 and 14 at baseline. Efficacy assessments were
performed at baseline, 4 weeks, 12 weeks, and at 28 weeks
(or earlier termination). Primary outcome measures included
the Clinician’s Interview-Based Impression of Change Plus
Caregiver Input (CIBIC-Plus) (Schneider et al 1997), and
the modified 19-item Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Inventory (ADCS-ADL19)
(Galasko et al 2005) at 28 weeks compared with baseline.
The CIBIC-Plus (Schneider et al 1997) assessment was
completed by experienced clinicians who did not know the
results of any of the other assessments and were unaware
of any adverse events (AEs) reported by the participants.
Although memantine lacked a statistically significant effect
on the CIBIC-Plus in the Last Observation Carried Forward
(LOCF) analysis (4.5 vs 4.8, p=0.06, Table 1), a significant
benefit was observed in the analysis of patients who
completed the 28-week study (4.4 vs 4.7, p=0.03). Scores
on the ADCS-ADL19 were similar in both groups at baseline,
but at 28 weeks, patients in the memantine group had
significantly better outcome than patients in the placebo
group in both the LOCF (–3.1 vs –5.2, p=0.02, Table 1) and
completers (–2.5 vs –5.9, p=0.003) analyses. Beneficial
effects of memantine were also reported for three of the
other outcome measures using LOCF analysis: the Severe
Impairment Battery (SIB) (Schmitt et al 1997) (–4.0 vs –
10.1, p<0.001, Table 1); the Functional Assessment Staging
(FAST) scale (Sclan and Reisberg 1992) (0.2 vs 0.6, p=0.02);
and the Resource Utilisation in Dementia (RUD) instrument
(which assesses caregiver burden and economic data).
Response rate (predefined as improvement or no
deterioration in the CIBIC-Plus and either the ADCS-ADL19
or SIB) was higher in the memantine group (29%) than in
the placebo group (10%; p< 0.001). The changes in the
MMSE (–0.5 vs –1.2, p=0.18) and GDS (0.1 vs 0.2, p=0.11)
did not differ significantly between the treatment groups.
In this trial, no significant differences were observed
between memantine and placebo in neuropsychiatric
symptoms, as assessed by the Neuropsychiatric Inventory
(NPI) (Cummings et al 1994) total change score (0.5 vs
3.8, p=0.33).
Following the initial report of Reisberg et al (2003)
secondary analyses have appeared that have shed additional
light on this study. A post hoc analysis of ADCS-ADL19
data by Rive et al (2004) showed that memantine-treated
patients were 3 times more likely (odds ratio [OR] = 3.03;
95% confidence intervals [CI] = [1.38, 6.66], p=0.006) to
remain autonomous after 28 weeks, even after controlling
for autonomy and severity at baseline. This finding was
confirmed by LOCF (OR = 2.31; 95% CI = [1.12, 4.76],
p=0.023) and completers (OR = 2.88; 95% CI = [1.15, 7.32],
p=0.024) analyses. Dependent patients had significantly
longer disease duration, poorer cognition, more behavioral
alterations, and higher total societal costs compared with
autonomous patients. By contrast, Livingston and Katona
(2004) employed a number needed to treat (NNT, the
number of subjects who need to be treated for one subject
to achieve a particular outcome) analysis of several outcome
measures from this study. They showed that memantine
(NNT 6-8) compared favorably with ChEIs (NNT 4-13) for
favorable response on the CIBIC-Plus, SIB, or ADCS-
ADL19 (Livingston and Katona 2004).
van Dyck et al study
A more recent study of memantine monotherapy in subjects
with moderate to severe AD (MEM-MD-01; website
summary available at www.forestclinicaltrials.com)
(van Dyck et al 2007) failed to demonstrate a statistically
significant benefit of memantine treatment compared with
placebo. This was a 24-week, randomized, double-blind,
placebo-controlled trial of memantine 10 mg twice daily
conducted in 350 outpatients with moderate to severe AD
recruited from 37 US centers. Inclusion criteria were:
age of 50 years or older, diagnosis of probable AD according
to NINCDS-ADRDA criteria (McKhann et al 1984),
and MMSE (Folstein et al 1975) score between 5 and 14.
Primary efficacy variables were the SIB (Schmitt et al 1997)
and the ADCS-ADL19 (Galasko et al 2005). Secondary
efficacy variables included the CIBIC-Plus (Schneider et al
1997), NPI (Cummings et al 1994), FAST (Sclan and
Reisberg 1992), BGP (van der Kam and Hoeksma 1989),
and BGP care dependence subscale. The central efficacy
analyses were conducted using the LOCF approach and
compared change from baseline between memantine and
placebo groups for the SIB, BGP, ADCS-ADL19, FAST, and
NPI using a 2-way analysis of covariance (ANCOVA), with
treatment group and center as main effects, and baseline as
covariate (least squares means; note that unadjusted within-
group mean changes are reported on the website summary
(www.forestclinicaltrials.com]). For the CIBIC-Plus, the
Cochran-Mantel-Haenszel (CMH) test using modified Ridit
scores (Van Elteren test) controlling for study center was
used to compare distributions between groups.Neuropsychiatric Disease and Treatment 2007:3(2) 250
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Prospectively defined analyses failed to demonstrate a
statistically significant benefit of memantine treatment
compared with placebo on the SIB at Week 24 end point (–2.0
vs –2.5, p=0.62), although a significant advantage was observed
for memantine at Weeks 12 and 18. The ADCS-ADL19 did not
differ significantly between groups at Week 24 endpoint (–2.0
vs –2.7, p=0.28) or in any other analysis. CIBIC-Plus scores
did not significantly favor memantine at Week 24 (4.3 vs
4.6, p=0.18) despite a significant advantage for memantine
at Weeks 12 and 18. Other secondary outcome measures
showed no significant treatment differences. Due to
violations of normality assumptions for the SIB and ADCS-
ADL19, post hoc non-parametric analyses were performed;
statistically significant benefit of memantine over placebo
was demonstrated for the SIB at Week 24, but not for the
ADCS-ADL19 (van Dyck et al 2007).
The discrepant results in the study of van Dyck et al
(2003) compared with those of Reisberg et al (2003) may
be attributable to methodological or subject differences;
however, variations in protocol design were minimal. The
study of van Dyck et al (2007) was of slightly shorter
duration than the trial by Reisberg et al (2003) (24 weeks
vs 28 weeks), but was otherwise of similar design. The
subject population of van Dyck et al (2007) compared
with that of Reisberg et al (2003) was somewhat older
(78.2 years vs 76.1 years) and contained a higher
percentage of women (71.4% vs 67.5%) and a lower
percentage of white participants (80.9% vs 90.1%). In
addition, 62.6% of patients in van Dyck et al (2007) had
previously been treated with ChEIs, compared with 31.3%
in the Reisberg et al (2003) study. However, in the study
of van Dyck et al (2007), post hoc analyses of potentially
confounding covariates (age, prior ChEI use) did not
substantially alter the results.
Combination therapy studies
The established efficacy of ChEIs in AD (Cummings
2003) naturally raised the question of whether
memantine would also provide clinical benefit for
moderate to severe stage patients already treated with
one of these drugs. In vitro studies have demonstrated
that memantine does not diminish the cholinesterase
inhibition of ChEIs suggesting the possibility of using
them in conjunction (Hartmann and Mobius 2003;
Periclou et al; 2004, Yao et al 2005). A “combination
therapy” study of memantine and the ChEI donepezil
has also recently been conducted.
Tariot et al study
This study involved 404 subjects with probable AD who
had received stable doses of donepezil for at least 3 months
who were randomized to receive memantine 10 mg twice
daily or placebo. This 24-week study included subjects over
the age of 50 years and with MMSE (Folstein et al 1975)
scores between 5 and 14 and was conducted at 37 US sites.
Subjects who were randomized to memantine treatment were
titrated in 5 mg weekly increments from a starting dose of 5
mg daily to 10 mg twice daily. Cognitive, functional, and
global outcome measures were obtained at baseline and at
the end of weeks 4, 8, 12, 18, and 24. The primary efficacy
measures were the change from baseline on the SIB (Schmitt
et al 1997) and the ADCS-ADL19 (Galasko et al 2005).
Secondary outcome measures included the CIBIC-Plus
(Schneider et al 1997), the NPI (Cummings et al 1994), and
the BGP (van der Kam and Hoeksma 1989).
Analyses were conducted using the LOCF approach.
Subjects treated with memantine had statistically significant
benefits on the SIB (0.9 vs –2.5, p<0.001) and ADCS-ADL19
(–2.0 vs –3.4, p=0.03) compared with placebo (Table 1).
Post hoc analyses of subjects completing the protocol also
showed that patients treated with memantine had statistically
significant benefits on the SIB (1.0 vs –2.4, p<0.001) and
ADCS-ADL19 (–1.7 vs –3.3, p=0.02). On secondary
measures, the CIBIC-Plus score was significantly better in
the memantine group (4.41 vs 4.66, p=0.03, Table 1)
compared with placebo. Overall, 55% of the subjects in the
memantine group were rated as unchanged or improved on
the CIBIC-Plus compared to 45% in the placebo group. The
total NPI change score was also lower in the memantine
group in both the LOCF (–0.1 vs 3.7, p=0.002) and
completers (–0.5 vs 2.9, p=0.01) analyses. On the BGP care
dependency subscale statistically significant improvement
was seen in the memantine group in the LOCF (0.8 vs 2.3,
p=0.001, Table 1) and completers (0.6 vs 2.2, p=0.001)
analyses.
A recent post hoc analysis of the effects of memantine
on the NPI data in the studies conducted by Reisberg et al
(2003) and Tariot et al (2004) showed that the change in
NPI total scores at endpoint was consistently in favor of
memantine treatment, reaching statistical significance in the
Tariot et al combination study (p=0.002) (Gauthier et al
2005). Memantine treatment showed a significant beneficial
effect in comparison to placebo in the NPI agitation/
aggression subscale in both studies (p=0.008; p=0.001). A
dichotomized analysis of the Reisberg et al (2003)
monotherapy study showed that there was significantly lessNeuropsychiatric Disease and Treatment 2007:3(2) 251
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agitation/aggression emerging in the memantine-treated
group compared to placebo (p=0.003). Factor analysis
demonstrated that hyperactivity accounted for 27% of the
data variance.
Memantine for mild to moderate
AD
Memantine has been evaluated in mild to moderate AD
patients in 3 major studies: 2 involving memantine
monotherapy, and 1 involving combination therapy with
ChEIs. All of these trials were conducted in community-
dwelling subjects and included samples of 403 subjects
(Peskind et al 2006), 318 subjects (Bakchine et al 2005),
and 433 subjects (Mem-MD-12; www.forestclinical
trials.com). The efficacy results of these studies (except
Bakchine et al (2005), for which mean change data are
unavailable) are summarized in Table 1 and the various
rating scales utilized are detailed in Table 2.
Monotherapy studies
Peskind et al study
A study of memantine monotherapy in subjects with mild
to moderate AD has recently been reported by Peskind et al
(2006). This was a randomized, double-blind, placebo-
controlled trial of memantine 10 mg twice daily, in which
403 community-dwelling subjects were followed for 24
weeks. This trial included male and female patients 50 years
or older, who had the diagnosis of probable AD by the
NINCDS-ADRDA criteria (McKhann et al 1984), and
MMSE (Folstein et al 1975) scores between 10 and 22
(inclusive). Primary outcome measures were the CIBIC-Plus
(Schneider et al 1997) and Alzheimer’s Disease Assessment
Scale-Cognitive subscale (ADAS-Cog) (Rosen et al 1984).
Changes from baseline on the primary end points of CIBIC-
Plus (4.2 vs 4.5, p<0.004), ADAS-Cog (–0.8 vs 1.1,
p<0.003) and NPI (–1.4 vs 2.1, p=0.01) using the LOCF
method favored memantine compared with placebo (see
Table 1). Scores on the ADCS-ADL23 (a version of the
ADCS-ADL validated for mild to moderate stage AD
patients), did not favor memantine compared to the placebo
group (–2.9 vs –3.0, p=0.89).
Bakchine et al study
A second study of memantine monotherapy in mild to
moderate AD patients has been conducted in Europe and
presented in abstract form (Bakchine et al 2005). Subjects
were included in the study, if they were 50 years or older,
had a diagnosis of probable AD according to NINCDS-
ADRDA (McKhann et al 1984) and DSM-IV-TR criteria, a
MMSE (Folstein et al 1975) score between 11 and 23, and a
Modified Hachinski Ischemia Score (Rosen et al 1980) of
≤4. Subjects in this study were randomized to receive either
memantine 20 mg daily or placebo in a 2:1 ratio. Of the 318
patients randomized to and treated with memantine, 85%
completed the study, compared with 91% of the 152 patients
randomized to the placebo group. In this 24-week study, on
the ADAS-Cog (Rosen et al 1984) memantine-treated
patients showed statistically significant improvement
relative to placebo treated patients at weeks 12 (p=0.01)
and 18 (p=0.016) but only nonsignificant numerical
superiority at week 24 endpoint (p=0.156). On the CIBIC-
Plus (Schneider et al 1997) memantine demonstrated
statistically significant superiority over placebo at weeks
12 (p=0.033) and 18 (p=0.012) but only numerical
superiority at week 24 endpoint (p=0.523).
Interestingly, the authors also pooled data from this study
(Bakchine et al 2005) and the US study by Peskind et al
(2006) and conducted a post hoc analysis of the datasets.
When using the protocol specified LOCF analysis, they
found that at week 24 there was a 1.9-point difference on
the ADAS-Cog (p=0.003) and 0.31-point difference on the
CIBIC-Plus (p=0.004). A statistically significant separation
of memantine from placebo was observed on both scales
from week 12 onwards. The authors concluded that based
on the dual responder criteria, a numerically greater
proportion of memantine-treated patients responded at every
assessment with statistical significance being met at Weeks
12 (p=0.001), 18 (p=0.001), and 24 (p=0.015) (Bakchine et
al 2005). Despite meeting statistical significance, these effect
sizes are smaller than those reported for approved ChEIs in
patients with mild to moderate AD, and their clinical
significance remains to be established.
Combination therapy studies
MEM-MD-12 Study
One “combination therapy” study of memantine has thus
far been conducted in mild to moderate stage AD
patients already stabilized on ChEIs (Mem-MD-12;
www.forestclinicaltrials.com). In a randomized, double-blind,
placebo-controlled trial evaluating memantine in outpatients
with AD, 216 subjects were randomized to memantine and
217 to placebo. Subjects were eligible for participation in
the study, if they were 50 years of age or older, had a
diagnosis of probable AD according to NINCDS-ADRDA
criteria (McKhann et al 1984) and a MMSE (Folstein et al
1975) score between 10 and 22 inclusive. Eligible patientsNeuropsychiatric Disease and Treatment 2007:3(2) 252
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must have received ongoing therapy with donepezil,
rivastigmine, or galantamine for at least 6 months with a
stable dose for 3 months prior to randomization. All patients
had to continue to receive ChEI therapy at a stable dose for
the duration of the study. The primary efficacy parameters
were the change from baseline in the total ADAS-Cog
(Rosen et al 1984) and CIBIC-Plus (Schneider et al 1997)
rating at Week 24 using the LOCF approach. A 2-way
ANCOVA model with treatment group and study center as
factors and baseline score as covariate was used. 89.4% of
the subjects in the memantine/ChEI group completed the
study compared with 88.4% in the placebo/ChEI group. The
change in ADAS-Cog at Week 24 compared with baseline
was 0.4±0.4 for the memantine/ChEI group compared with
1.1±0.4 (p=0.184) in the placebo/ChEI group. On the
CIBIC-Plus, the scores at Week 24 were identical in both
groups at 4.4±0.1 (p=0.843). There was no statistically
significant difference between the two groups at Week
24 in any of the secondary efficacy parameters, including
ADCS-ADL23 (–2.9±0.5 vs –2.9±0.6), MMSE (–0.3±0.2
vs –0.7±0.2) or change in  NPI total score (1.1±0.8 vs
0.6±0.7) (www.forestclinicaltrials.com).
Limitations of memantine studies
A potential limitation common to all previous memantine
studies contained in this review is the use of LOCF as a
means of imputing missing data. Although a convenient and
acceptable way of ensuring maximal use of trial data, the
LOCF method may introduce biases, including favoring the
treatment group with the higher drop out rate in a
deteriorating illness. Several alternative statistical methods
have emerged for dealing with missing data including,
random regression, multiple imputation, and generalized
estimating equations (GEE) (Zeger and Liang 1986). The
Generalized Estimating Equations (GEE) approach, an
adaptation of generalized linear modeling (Zeger and Liang
1986), is particularly promising, as it takes into account
correlation between repeated observations on individual
subjects that occurs when subjects are evaluated with the
same outcome measures over time.
A recent post hoc responder analysis of the Tariot et al
study (Tariot et al 2004) has been undertaken in which
missing data were imputed using the GEE approach and
treatment response was evaluated using three sets of
responder criteria (van Dyck et al 2006). The results of this
study showed that when treatment response required
cognitive improvement relative to baseline, memantine
yielded higher response rates than placebo. When treatment
response was alternatively defined as stabilization of
individual outcomes, memantine resulted in significantly
higher response rates than placebo for all outcomes. More
conservative definitions of response that required
simultaneous stabilization on multiple outcome measures
again favored memantine treatment for 6 of 10 combinatorial
definitions. These results suggest that when an alternative
method (to LOCF) is used to impute missing data,
memantine treatment is still associated with favorable
treatment response (improvement and stabilization of
symptoms, across multiple outcomes) (van Dyck et al 2006).
Another limitation pertains to the design of the available
combination therapy studies. Combination studies of
memantine with ChEIs have thus far compared a memantine/
ChEI group with a placebo/ChEI group. The lack of placebo
only and memantine only arms in these studies limits the
interpretability of the results, as the efficacy of the individual
drugs, their combination, and placebo cannot simultaneously
be compared. In a recent commentary, Fox et al (2006) have
concluded that the available data do not justify the use of
combination therapy.
Safety and tolerability
In the trials detailed in this review, memantine has shown
excellent safety and tolerability, with a frequency of adverse
events (AEs) similar to placebo. In the Winblad and Poritis
study in institutionalized patients (Winblad and Poritis
1999), 22% of the memantine-treated subjects had AEs
compared with 21% of placebo-treated subjects. For the six
outpatient trials of memantine reported in this review
(Reisberg et al 2003; Tariot et al 2004; Bakchine et al 2005;
Peskind et al 2006; van Dyck et al 2007) (and the Mem-
MD-12; www.forestclinicaltrials.com) overall treatment-
emergent AEs are summarized in Table 3. In the two
published studies of moderate to severe stage AD by
Reisberg et al, and Tariot et al, subjects in the memantine
groups did not experience significantly more AEs than
subjects taking placebo (84% vs 87%, and 78% vs 72%,
respectively) (Reisberg et al 2003; Tariot et al 2004). Most
AEs were rated as mild to moderate and unrelated to study
medication. In the Reisberg et al trial, subjects on placebo
had a higher incidence of agitation (32% vs 18%) and
urinary tract infection (6% vs 2%) compared with the
memantine-treated patients. In the Tariot et al study, AEs
that occurred in >5% of the memantine group and with an
incidence at least twice that of the placebo group were
headache (6.4% vs 2.5%, p=0.09), and confusion (7.9% vsNeuropsychiatric Disease and Treatment 2007:3(2) 253
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2%, p=0.01) (Tariot et al 2004). Conversely, diarrhea (8.5%
vs 4.5%) and fecal incontinence (5% vs 2%) were more
commonly seen in the placebo-treated group (Tariot et al
2004).
In both the Reisberg et al and Tariot et al studies,
premature discontinuations from the study due to AEs were
actually more common in the placebo groups (Reisberg et
al: 17% vs 10%; Tariot et al: 12% vs 7%) than in the
memantine groups. In the Reisberg et al study the AE most
often associated with premature discontinuation was
agitation, resulting in discontinuation in 7% of placebo-
treated patients, compared with 5% of memantine-treated
patients (Reisberg et al 2003). By contrast, in the Tariot et
al study the AE most often associated with premature
discontinuation was confusion, resulting in discontinuation
in 1.5% of placebo-treated patients, compared to 2% of
memantine treated patients (Tariot et al 2004).
In the study of van Dyck et al (MEM-MD-01) (2007),
memantine was well tolerated with similar rates of treatment
emergent AEs in the memantine (73.6%) and placebo
(72.7%) groups. The only AE that occurred in 5% or more
of the memantine group, and with an incidence at least twice
that of the placebo group, was hypertension (7.9% vs 2.3%,
respectively). AEs that occurred in 5% or more of the
placebo group, and with an incidence at least twice that of
the memantine group, were insomnia (5.2% vs 2.2%,
respectively) and headache (6.4% vs 1.7, respectively). There
was less agitation reported in the memantine group than the
placebo group (9.0% vs 14.0%, respectively). A similar
percentage of participants in both groups discontinued the
study prematurely due to AEs (placebo, 13.4% vs
memantine, 12.4%). The AE most often associated with
discontinuation was agitation, which occurred in 3.5% of
placebo-treated patients and 1.7% of memantine-treated
patients.
In the study by Peskind et al (2006), AEs occurred in
71% and 74% of the memantine and placebo groups,
respectively. The only AE that occurred in 5% or more of
the memantine group, and with an incidence at least twice
that of the placebo group, was somnolence (7.0% vs 1.0%)
group, whereas subjects treated with placebo were more
likely to develop depression (5.0% vs 2.0%) and upper
respiratory tract infection (6.0% vs 2.0%) (Peskind et al
2006).
In the Bakchine et al study (2005), 56% of the
memantine-treated patients had treatment emergent side-
effects compared with 52.6% patients on placebo. The only
AE that occurred in 5% or more of the memantine group,
and with an incidence at least twice that of the placebo group,
was headache (5.7% vs 2.0%). Agitation (4.6% vs 1.6%)
was slightly more common in the placebo group.
In the MEM-MD-12 study, 10.6 % of the subjects withdrew in
the memantine/ChEI group compared with 11.6% in the placebo/
ChEI group. The reason for withdrawal in the two groups due to
AEs was (6.0% vs 7.9%). Treatment-emergent AEs were seen in
79.7% of the memantine/ChEI group compared with the 77.8% of
the placebo/ChEI group. No AEs occurred in 5% or more of the
memantine/ChEI group, and with an incidence at least twice that
of the placebo/ChEI group (www.forestclinicaltrials.com).
Serious adverse events (SAEs) have been very
uncommon across all memantine studies. In the study by
Winblad and Poritis (1999), 5% of the memantine subjects
had SAEs compared with 6% in the placebo group. One
patient died before randomization, whereas 4 patients
died in each randomized treatment arm (memantine and
placebo). For all SAEs, the causal relationship to study
medication was rated as “unlikely” by the investigators.
In the study by Reisberg et al (2003), SAEs were reported
in 13% of subjects receiving memantine compared with
18% receiving placebo. There were 7 deaths, 2 of which
occurred in the memantine
 group. Most SAEs, including
all of the deaths, were considered to be unrelated
 to study
medication. No clinically relevant changes in vital signs,
laboratory data, or electrocardiography measurements
were reported in any of the studies. In the study of van
Dyck et al (MEM-MD-01) (2007), SAEs were less
common in the memantine group (14.6% vs 16.9%)
compared with placebo. Five subjects in the memantine
group had fatal SAEs compared with 3 fatal SAEs in the
placebo group. The investigators concluded that these
SAEs were not related to the study drug (van Dyck et al
2007). In the study of Peskind et al (2006) SAEs occurred
in 10% of the participants in each treatment group.
Overall the type and incidence of SAEs were similar
between groups. One participant death occurred in each
group during the trial, neither considered treatment-
related by the investigators (Peskind et al 2006). In the
Mem-MD-12 study there were a total of 3 fatal SAEs in
the memantine/ChEI group compared with 2 in the
placebo/ChEI group, but they were determined to be
unrelated to the trial drugs (www.forestclinicaltrials.com).
Dosing schedule
In adult and elderly patients the recommended maintenance
dose of memantine is 20 mg daily, administered as 10 mg
twice daily (Forest Laboratories 2003). The recommendedNeuropsychiatric Disease and Treatment 2007:3(2) 256
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starting dose for memantine is 5 mg daily and the dosage
titration is by 5 mg daily in weekly increments to 10 mg
twice daily by Week 4. In subjects with impaired creatinine
clearance (5–29 mL/min) a target dose of 5 mg BID is
recommended (Forest Laboratories 2003). However, a new
study conducted in patients with moderate to severe AD
has shown that once-daily dosing of memantine at 20 mg
was as well tolerated as the twice-daily dosing (Jones et al
2005).
Memantine in clinical practice
Memantine was first developed in Europe in the 1970s,
but its action at NMDA receptors was not recognized until
the late 1980s (Parsons et al 1999). It was subsequently
registered in Germany in 1989 for the treatment of cerebral
ischemia and AD. Since then, based on studies including
those detailed in this review (Winblad and Poritis 1999;
Reisberg et al 2003; Tariot et al 2004), it has been approved
for use in the United States in patients with moderate to
severe AD and in Europe for patients with moderately
severe to severe AD. Moreover, based in part on the study
of Peskind et al (2006), applications have been made to
the regulatory authorities in Europe and in the United
States to expand its use to mild to moderate AD (Forest
Laboratories 2004; Lundbeck Pharmaceuticals 2004).
Although the United States Food and Drug Administration
(FDA) has issued a non-approvable letter for this expanded
indication, the matter remains under discussion (Forest
Laboratories 2005). Data supporting the use of ChEIs in
more advanced stages of AD are limited. In these severe
patients, the use of memantine may therefore become even
more important.
Although memantine is approved only for AD, two double-
blind studies have suggested possible beneficial effects of
memantine in patients with vascular dementia (Orgogozo et al
2002; Wilcock et al 2002). A pooled analysis of these studies
further suggested that memantine may be more effective in
subjects with small-vessel disease (white matter lesions and
or lacunae) (Mobius and Stoffler 2002). Given that 40%–50%
of patients with AD have these vascular changes in the brain,
these findings are encouraging.
Cost effectiveness
Despite the accumulated data on the beneficial effects of
memantine in patients with AD, a preliminary evaluation
by The National Institute for Clinical Excellence (NICE) in
the United Kingdom (April 2006) has concluded that “on
the basis of current evidence on clinical effectiveness
memantine could not reasonably be considered a cost-
effective therapy for moderately severe to severe Alzheimer’s
disease” (www.nice.org.uk/, last accessed 25 April 2006).
This was in contrast to the NICE conclusion regarding
ChEIs that “the resulting estimates of cost effectiveness
could be considered sufficiently acceptable to allow the
prescribing of AChE inhibitors for people with
Alzheimer’s disease and moderate cognitive impairment
(MMSE scores between 10 and 20)” (www.nice.org.uk/,
last accessed 25 April 2006).”
However, a recent review of multinational
pharmacoeconomic data concluded that the limited available
data suggest the cost-effectiveness of memantine treatment
when compared with no treatment in patients with moderate
to severe AD (Plosker and Lyseng-Williamson 2005). This
conclusion was further supported by a Swedish study
showing that, compared with no treatment, memantine
treatment was predicted to be associated with lower costs
of care, longer time to dependence and institutionalization,
and gains in quality-adjusted life-years (Jonsson 2005). The
author concluded that from a public payer’s perspective, the
observed effect of memantine on cognitive and physical
function is predicted to translate into economic benefits that
offset the added treatment cost.
Conclusion
In conclusion, well-designed studies have demonstrated that
memantine is safe and effective in modifying the progression
of cognitive, functional and global outcomes in patients with
moderate to severe AD, either as monotherapy or in combination
with the ChEI donepezil. Although there is still debate on the
efficacy of this medication in the treatment of earlier stages of
this disease, emerging data suggest its potential benefits in
patients with mild to moderate AD. Despite recent NICE
recommendations indicating that memantine is not cost
effective and that it should be prescribed only as part of clinical
studies, preliminary pharmacoeconomic data analyses support
the use of memantine as a cost-effective treatment in the AD
patient population.
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